Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia
|Upper Respiratory Tract Infection Asthma||Drug: Arm 1 Oral Cortico Steroids||Phase 4|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia|
- Reduction of representation to Health Services for Exacerbation of URTI induced asthma [ Time Frame: One year ]To review the effect of medication given at early onset of symptoms have on reducing the presentation to Health Services and Emergency Departments.
|Study Start Date:||April 2011|
|Estimated Study Completion Date:||June 2016|
|Primary Completion Date:||May 2012 (Final data collection date for primary outcome measure)|
Active Comparator: Arm 1 Oral Cortico Steroid
A filled prescription will be given to be used upon early onset of symptoms.
Drug: Arm 1 Oral Cortico Steroids
Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.
Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )
Other Name: Prednisone
No Intervention: Usual care for Asthma treatment
monitor the readmission of URTI induced asthma in children over a 12 month period
In Canada, asthma affects more the 12% of children. Exacerbation are a common feature of asthma. In children, upper respiratory tract infection (URTI's) are responsible for over 80% of asthma exacerbation.
Experts in asthma care acknowledge this critical problem and have developed guidelines to reduce asthma exacerbation.
The criteria for participation in this study to have 2 or more presentations to a Health Service centre in the past 12 months for URTI induced asthma. These patients will be followed and interviewed monthly over a 12 month period to investigate whether the use of Oral cortico-steroids upon early onset of URTI induced asthma prevents the need for presentation to hospital
Please refer to this study by its ClinicalTrials.gov identifier: NCT01326494
|Canada, British Columbia|
|BC Children's Hospital|
|Vancouver, British Columbia, Canada, V6H 3V4|
|Principal Investigator:||Bruce Carleton, B.Pharm, Pharm.D.||The University of British Columbia|